Genentech's Lucentis Gains FDA Approval For Macular Edema, Expands Market Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech's Lucentis is now approved to treat macular edema following retinal vein occlusion, in addition to wet eye macular degeneration.
You may also be interested in...
CMS Reverses Avastin Reimbursement Limits For Macular Degeneration In Physicians' Office
Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.